This phase I/II trial is trying to understand how much targeted therapy is required and if it is safe to use for the treatment of B-cell lymphoma that have gotten worse, not responded or come back on prior treatments.
This trial is treating patients with B-cell lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
This is a single arm, dose escalation and expansion trial in which eligible patients will receive Epcoritamab every 28 days.
The purpose of the escalation part of the trial is to determine the maximum tolerated dose and the recommended phase 2 dose (RP2D) as well as to establish the safety profile of epcoritamab GEN3013 (DuoBodyÂ®-CD3xCD20) in patients with relapsed, progressive or refractory B-Cell Lymphoma. In the expansion part, additional patients will be treated with epcoritamab to further explore and determine the safety and efficacy of epcoritamab.
Recruiting Hospitals Read More